BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
glucose metabolic process
,
Diabetes mellitus
,
Pancreas
,
Amniocentesis
,
Tamoxifen
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
C ROS
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Drug target sets for approved compounds
Cells with Reactive Oxygen Species (ROS) high compared to ROS low cells in cancer cell lines
Explore Curated Studies Results
Literature
Most Relevant Literature
Allosteric autoactivation of SOS and its kinetic mechanism.
Relating cellular signaling timescales to single-molecule kinetics: A first-passage time analysis of…
Insight into the C-terminal SH3 domain mediated binding of Drosophila Drk to Sos and Dos.
Development of Noonan syndrome by deregulation of allosteric SOS autoactivation.
Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562
Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMIā¢) Loaded With Doxorubicin
A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patient…
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lym…
A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ